Amifostine Patent Expiration
Amifostine is Used for administering the drug product. It was first introduced by Legacy Pharma Inc Sezc
Amifostine Patents
Given below is the list of patents protecting Amifostine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Ethyol | US5994409 | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
Dec 08, 2017
(Expired) | Legacy |
| Ethyol | US5424471 | Crystalline amifostine compositions and methods of the preparation and use of same |
Jul 31, 2012
(Expired) | Legacy |
| Ethyol | US5591731 | Crystalline amifostine compositions |
Jul 31, 2012
(Expired) | Legacy |
Amifostine's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Amifostine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer. | Xerient Pharma | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1, PHASE2 |